成人先天性心脏病患者机械循环支持植入结局:INTERMACS注册分析
基于INTERMACS注册2006至2015年16182例患者,其中126例成人先天性心脏病(ACHD)患者接受机械循环支持。ACHD患者更年轻且更多以桥接移植为目的,双心室辅助装置/全人工心脏(BiVAD/TAH)支持比例更高。ACHD与无ACHD的LVAD患者生存相似,BiVAD/TAH支持者死亡率更高。
要点
- ACHD患者LVAD支持生存与无ACHD患者相似。
- BiVAD/TAH支持是死亡的独立预测因素。
- ACHD患者BiVAD/TAH支持者INTERMACS 1级比例更高。
核心结论
- ACHD患者接受LVAD支持生存与无ACHD患者相似,BiVAD/TAH支持者死亡率更高。
研究设计与样本
- 回顾性注册分析,纳入INTERMACS 2006年6月23日至2015年12月31日16182例患者,其中ACHD 126例。
主要发现
- ACHD患者126例,系统形态左心室63例、系统形态右心室45例、单心室17例。
- ACHD患者更年轻(42岁±14 vs 56岁±13;p<0.0001),更常以桥接移植为目的(45% vs 29%;p<0.0001)。
- ACHD患者BiVAD/TAH支持比例更高(21% vs 7%;p<0.0001)。
- BiVAD/TAH支持的ACHD患者INTERMACS 1级比例高于LVAD支持者(35% vs 15%;p=0.002)。
- BiVAD/TAH支持是唯一独立与死亡相关的变量(早期风险比4.4;95%CI 1.8-11.1;p=0.001)。
关键数值与推荐
- ACHD与无ACHD的LVAD患者生存相似;BiVAD/TAH支持者生存更差。
- ACHD患者心室形态与死亡率无关。
临床怎么用
- LVAD可作为ACHD晚期心衰的治疗选择之一。
- 需BiVAD/TAH支持的ACHD患者死亡风险更高,应关注INTERMACS分级。
局限性
- 回顾性注册研究,ACHD样本量较小(126例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adults with congenital heart disease represent an expanding and unique population of patients with heart failure (HF) in whom the use of mechanical circulatory support (MCS) has not been characterized. We sought to describe overall use, patient characteristics, and outcomes of MCS in adult congenital heart disease (ACHD). METHODS: All patients entered into the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) between June 23, 2006, and December 31, 2015, were included. Patients with ACHD were identified using pre-operative data and stratified by ventricular morphology. Mortality was compared between ACHD and non-ACHD patients, and multivariate analysis was performed to identify predictors of death after device implantation. RESULTS: Of 16,182 patients, 126 with ACHD stratified as follows: systemic morphologic left ventricle (n = 63), systemic morphologic right ventricle (n = 45), and single ventricle (n = 17). ACHD patients were younger (42 years ± 14 vs 56 years ± 13; p < 0.0001) and were more likely to undergo device implantation as bridge to transplant (45% vs 29%; p < 0.0001). A higher proportion of ACHD patients had biventricular assist device (BiVAD)/total artificial heart (TAH) support compared with non-ACHD patients (21% vs 7%; p < 0.0001). More ACHD patients on BiVAD/TAH support were INTERMACS profile 1 compared with patients on systemic left ventricular assist device (LVAD) support (35% vs 15%; p = 0.002). ACHD and non-ACHD patients with LVADs had similar survival; survival was worse for patients on BIVAD/TAH support. BiVAD/TAH support was the only variable independently associated with mortality (early phase hazard ratio 4.4; 95% confidence interval, 1.8-11.1; p = 0.001). For ACHD patients receiving MCS, ventricular morphology was not associated with mortality. CONCLUSIONS: ACHD patients with LVADs have survival similar to non-ACHD patients. Mortality is higher for patients requiring BiVAD/TAH support, potentially owing to higher INTERMACS profile. These outcomes suggest a promising role for LVAD support in ACHD patients as part of the armamentarium of therapies for advanced HF.
引用
- VanderPluym CJ, Cedars A, Eghtesady P, et al. Outcomes following implantation of mechanical circulatory support in adults with congenital heart disease: An analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). J Heart Lung Transplant. 2017. PMID: 28365175. doi:10.1016/j.healun.2017.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。